Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,799 total articles
Supernus Pharmaceuticals announced a partnership with professional snowboarder Chloe Kim to raise awareness about adult ADHD and promote Qelbree, their non-stimulant ADHD medication. Qelbree, approved by the FDA five years ago, has become the top prescribed branded non-stimulant ADHD treatment with 3 million prescriptions. The collaboration aims to…
Amarin Corporation highlighted multiple presentations at the ESC Congress 2026 showcasing new data from the REDUCE-IT trial and related mechanistic studies. The findings advance understanding of treatment adherence, cardiovascular outcomes, lipoprotein(a) biology, and coagulation pathways related to icosapent ethyl (IPE). The ESC/ERA 2026 guideline…
StepStone Group Inc., a global private markets investment firm managing approximately $913 billion in total capital, announced that its executives will present at the Barclays Global Financial Services Conference on September 14, 2026. The event will be webcast live and available for replay on StepStone's website.
Elicio Therapeutics, a clinical-stage biotechnology company focused on immunotherapies for KRAS-driven cancers, announced that its CEO and CSO will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in September 2026. The company develops next-generation, off-the-shelf immunotherapies targeting KRAS mutat…
CPS Technologies Corp. announced its first defense-related order for tungsten alloy components made using its proprietary QuickSet Injection Molding technology, marking the largest contract of its kind for the company. The order comes from a U.S. military research group and supports the ongoing development funded by a $1.15 million U.S. Army STTR a…
Kalaris Therapeutics, a clinical-stage biotech company focused on retinal disease treatments, announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference. The company will discuss its lead candidate, TH103, an investigational dual-action anti-VEGF biologic in Phase 1b/2 trials for neovascular Age-related Macular Degen…
Aqua Metals has signed a six-year non-binding letter of intent with WMC Group AG to cover 100% of the planned lithium carbonate production from its Project Headwaters, expected to be the first commercial-scale deployment of its AquaRefining™ technology in the U.S. The project aims to produce around 7,000 metric tons of lithium carbonate by 2032, va…
Gentex Corporation announced a quarterly cash dividend of $0.12 per share payable on October 21, 2026, to shareholders on record as of October 7, 2026. The dividend reflects the company’s ongoing commitment to returning value to shareholders.
Castellum, Inc., a cybersecurity and electronic warfare company, announced that its subsidiary GTMR received a $32.8 million modification to its existing NAVAIR PMA-290 Special Missions contract. This expands the contract ceiling to $136.2 million and covers extensive technical and program support across multiple intelligence, surveillance, reconna…
Viasat, Inc. announced that its ViaSat-3 F3 satellite has entered service, providing increased satellite communication capacity across the Asia-Pacific region. This launch marks the start of revenue operations for one of the most advanced high throughput satellites, enabling growth opportunities with flexible, high-capacity broadband connectivity i…
Cadrenal Therapeutics announced positive feedback from a recent FDA Type D meeting regarding the Phase 3 registrational trial design for CAD-1005, a novel 12-LOX inhibitor targeting heparin-induced thrombocytopenia (HIT). The FDA agreed on a defined primary endpoint assessing progression of thrombosis, use of placebo control alongside standard anti…
BioVie Inc., a clinical-stage biopharmaceutical company focused on neurological and liver diseases, announced the completion of the treatment phase of its ADDRESS-LC Phase 2 trial evaluating bezisterim for neurological symptoms associated with Long COVID. Fully funded by a $13.13 million grant from the U.S. Department of War, the trial enrolled app…
Dillard's, Inc. (NYSE: DDS) announced the launch of the Kristen Nichols x Antonio Melani limited-edition fashion collection for Fall 2026. This exclusive collaboration features timeless, elegantly tailored wardrobe staples blending American and European influences, available nationwide and online starting August 31, 2026. The collection highlights …
OnKure Therapeutics, a clinical-stage biopharmaceutical company focused on developing precision medicines for vascular anomalies and cancers, announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference where senior management will engage in one-on-one investor meetings. The company focuses on small molecule drugs targ…
PennantPark Floating Rate Capital Ltd.'s joint venture, PennantPark Senior Secured Loan Fund I LLC, has successfully reset a $316.7 million securitization, lowering its weighted average cost of capital from SOFR +2.31% to SOFR +1.82%. The transaction, supported by strong investor demand, extends the maturity of the debt to 2038 and reinforces the c…
Beyond Air, Inc. announced that the FDA has granted Breakthrough Device Designation to its LungFit GO system as a treatment for nontuberculous mycobacterial pulmonary disease (NTM-PD). This designation recognizes the device's potential to address significant unmet medical needs in difficult-to-treat lung infections. LungFit GO enables safe, high-do…
AEON Biopharma, a biopharmaceutical company focusing on developing ABP-450, a biosimilar to BOTOX for therapeutic use, announced its participation in investor meetings at Lake Street Capital Markets' 10th Annual Best Ideas Growth Conference. The company is advancing full-label U.S. market entry for ABP-450, aiming to capture a share of the over $3 …
Expion Energy, a US-based company listed on Nasdaq under ticker XPON, has appointed oil and gas industry veteran Marc Jarvis to its Board of Directors. This move complements recent executive hires and supports Expion’s strategic push into the oil and gas sector, particularly targeting growth in Eastern Louisiana near emerging hyperscale data center…
Chemomab Therapeutics, a Nasdaq-listed clinical stage biotech company focusing on immune-fibrotic diseases, announced its CEO will present at the H.C. Wainwright 28th Annual Global Investor Conference. The company is preparing to merge with Scipher Medicine, a precision medicine firm specializing in rheumatoid arthritis, with the merger expected to…
Alpha Tau Medical Ltd. announced the completion of patient enrollment in its IMPACT multicenter pilot study evaluating Alpha DaRT® combined with first-line chemotherapy for unresectable pancreatic cancer. Enrollment was expanded from 12 to 48 patients due to strong demand. Data release is expected in early 2027 to inform a pivotal study. The study …
Teladoc Health, a leader in virtual care, has appointed Michael Grasher as its new Chief Financial Officer. Grasher brings over 30 years of experience in financial leadership roles within insurance and financial services sectors, including CFO roles at both public and private companies. His appointment is expected to support Teladoc's strategy for …
Innventure, Inc. announces key leadership changes including Bruce Brown as new Board Chairman, Catriona Fallon as Audit Committee Chair, and Dr. William Grieco's accelerated assumption of CEO role effective September 1, 2026. These governance changes coincide with a strategic review focusing on cost reductions, funding alternatives, and evaluation …
Pasqal, a Nasdaq-listed leader in neutral-atom quantum computing, has entered into a strategic research collaboration with Saudi Arabia's King Abdulaziz City for Science and Technology (KACST) to develop quantum-safe cryptographic solutions and advance quantum technology research. This partnership supports Saudi Arabia's Vision 2030 to build a nati…
Emergent BioSolutions announced that it has won a standing offer contract from the Government of Canada to supply NARCAN® Nasal Spray from October 2026 through September 2029, with an option to extend for two more years. This agreement facilitates increased access to emergency opioid overdose treatment in federal, provincial, and territorial organi…
Emergent BioSolutions has reaffirmed its commitment to opioid overdose education and preparedness, highlighting its Ready to Rescue campaign targeting U.S. college campuses and its partnership with influential figures like Zac Clark and Davis Schneider. The company promotes wider access and awareness of its FDA-approved over-the-counter NARCAN® Nas…
